Production (Stage)
Amicus Therapeutics, Inc.
FOLD
$6.22
-$0.04-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 543.14M | 528.30M | 493.67M | 455.66M | 423.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 543.14M | 528.30M | 493.67M | 455.66M | 423.49M |
| Cost of Revenue | 51.07M | 52.94M | 49.43M | 46.10M | 43.95M |
| Gross Profit | 492.07M | 475.35M | 444.24M | 409.56M | 379.54M |
| SG&A Expenses | 327.18M | 323.38M | 306.95M | 297.50M | 289.34M |
| Depreciation & Amortization | 8.23M | 8.55M | 8.69M | 8.75M | 8.77M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 495.35M | 494.23M | 479.27M | 481.08M | 481.27M |
| Operating Income | 47.79M | 34.06M | 14.40M | -25.43M | -57.79M |
| Income Before Tax | -3.22M | -28.76M | -68.35M | -99.84M | -140.47M |
| Income Tax Expenses | 26.16M | 27.35M | 36.34M | 19.70M | 6.61M |
| Earnings from Continuing Operations | -29.37 | -56.11 | -104.69 | -119.54 | -147.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.37M | -56.11M | -104.69M | -119.54M | -147.07M |
| EBIT | 47.79M | 34.06M | 14.40M | -25.43M | -57.79M |
| EBITDA | 56.02M | 42.61M | 23.09M | -16.68M | -49.02M |
| EPS Basic | -0.10 | -0.19 | -0.35 | -0.40 | -0.49 |
| Normalized Basic EPS | 0.00 | -0.04 | -0.09 | -0.16 | -0.25 |
| EPS Diluted | -0.10 | -0.19 | -0.35 | -0.40 | -0.49 |
| Normalized Diluted EPS | 0.00 | -0.04 | -0.09 | -0.16 | -0.25 |
| Average Basic Shares Outstanding | 1.22B | 1.22B | 1.21B | 1.20B | 1.19B |
| Average Diluted Shares Outstanding | 1.22B | 1.22B | 1.21B | 1.20B | 1.19B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |